News

Phase 3 DURAVYU insert misses key vision endpoint in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

A roundup of Ophthalmology Times' H1 2026 refractive coverage shows the field moving toward individualized care through adjustable lens outcomes, AI-assisted planning, and refined pediatric myopia monitoring.

Byron Lam, MD, and Benjamin Bakall, MD, PhD, discuss what an FDA approval of tinlarebant could mean for the Stargardt disease type 1 standard of care.

Host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Flaxel and Dr. Rudnick about how a home monitoring device could reshape treatment decisions and reduce office visits for patients with wet AMD.

EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.

Approach centers on pressure-free messaging and optometric education

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

Margaret A. Chang, MD, MS, on MK-8748's dual Tie2/VEGF mechanism, what MALBEC's data must show to shift wet AMD care, and where DME and RVO fit next.

Wnt modulators, sustained-release TKIs, and topical steroids are in phase 3 trials for DME, offering alternatives to anti-VEGF injections.

Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.

A maternal high-fat diet can negatively affect the retinal structure in mice.

Ahead of his November 10, 2026, start date, the incoming Duke ophthalmology chair shares his vision for research, training, and the integration of AI and data science.

FDA grants priority review to Belite Bio's tinlarebant NDA for Stargardt disease type 1, setting a February 2027 PDUFA date for a potential first STGD1 therapy.

Real-world insights into Artelac Complete, a preservative-free, multi-component tear substitute

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

25.5% of patients labeled with MacTel2 didn't meet diagnostic criteria, most often due to cystic OCT changes and telangiectatic vessels mistaken for the disease.

The trial is evaluating the company’s orally administered synthetic cannabinoid, ART27.13

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.

Bakall on 3-year REMAIN data for MCO-010 in retinitis pigmentosa: durable 3-line acuity gains, why genotype did not matter, and which patients responded best.

Harrow will acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for up to $100 million, complementing its cyclosporine product Vevye.

Capsulotomy size may not be refractive neutral: a larger opening shifted the IOL about 120 µm posteriorly in thin lenses and anteriorly in thick ones in a paired-eye study.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.

Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.

Waste, cost and carbon are converging to reshape how cataract centres choose instruments.

In the latest episode of The Wills Retina Report, Dr. Regillo and Dr. Hsu discuss why sustained delivery with the port delivery system may outperform even closely monitored intermittent injections.

This article discusses the current treatments being investigated during the first half of 2026.